2009
Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone
Bruce RD, Altice FL, Moody DE, Lin SN, Fang WB, Sabo JP, Wruck JM, Piliero PJ, Conner C, Andrews L, Friedland GH. Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir/ritonavir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug And Alcohol Dependence 2009, 105: 234-239. PMID: 19726139, PMCID: PMC2779257, DOI: 10.1016/j.drugalcdep.2009.07.007.Peer-Reviewed Original ResearchConceptsTPV/rBuprenorphine/naloxonePharmacokinetic interactionsBuprenorphine/naloxone therapySteady-state pharmacokinetic evaluationOpioid replacement therapyHIV-negative subjectsHIV-seronegative subjectsOpioid withdrawal symptomsHistorical control subjectsTipranavir/ritonavirConcentration-time profilesRTV levelsAntiretroviral medicationsDosage modificationNaloxone therapyTreatment medicationsOpioid dependenceReplacement therapyWithdrawal symptomsControl subjectsPharmacokinetic effectsHIV therapyPharmacokinetic evaluationNLX
2008
A randomized comparison of two instruments for measuring self-reported antiretroviral adherence
Mannheimer S, Thackeray L, Hullsiek K, Chesney M, Gardner E, Wu A, Telzak E, Lawrence J, Baxter J, Friedland G, Aids F. A randomized comparison of two instruments for measuring self-reported antiretroviral adherence. AIDS Care 2008, 20: 161-169. PMID: 18293124, DOI: 10.1080/09540120701534699.Peer-Reviewed Original ResearchConceptsSelf-reported adherenceImmunologic outcomesAntiretroviral adherenceStudy visitRecall instrumentSelf-reported antiretroviral adherenceCD4 cells/HIV resistance mutationsMultidrug-resistant HIVSelf-report instrumentVirologic failureAntiretroviral medicationsHIV diseaseMonth 12Randomized comparisonClinical trialsTreatment strategiesAdherence levelsResistance mutationsAdherenceCells/VisitsTrialsDaysMedianDifferential adherence to combination antiretroviral therapy is associated with virological failure with resistance
Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, MacArthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008, 22: 75-82. PMID: 18090394, PMCID: PMC2405889, DOI: 10.1097/qad.0b013e3282f366ff.Peer-Reviewed Original ResearchConceptsNon-nucleoside reverse transcriptase inhibitorInitial virological failureCombination antiretroviral therapyVirological failureAntiretroviral resistanceAntiretroviral therapyTreatment-naive HIV-1-infected individualsDifferential adherenceProspective clinical trial dataHIV-1-infected individualsMultivariate Cox regression analysisProtease inhibitorsTime-updated variablesCox regression analysisDisease-specific factorsReverse transcriptase inhibitorClinical trial dataMedication resistanceAntiretroviral medicationsRandomized trialsMonths 1Transcriptase inhibitorSame timepointsTrial dataSecondary analysisPharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice
Bruce RD, Altice FL, Friedland GH. Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: implications and management for clinical practice. Expert Review Of Clinical Pharmacology 2008, 1: 115-127. PMID: 24410515, DOI: 10.1586/17512433.1.1.115.Peer-Reviewed Original ResearchPharmacokinetic drug interactionsDrugs of abuseDrug interactionsAntiretroviral therapyHIV treatmentActive illicit drug useClinical implicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesIllicit drug useHIV/AIDSMetabolism of drugsPharmacokinetic interaction studyAntiretroviral medicationsCase seriesTreatable diseaseClinical consequencesClinical practiceDrug useMedical consequencesSubstance abuseTherapyDrugsAbuse
2006
Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications
Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic Drug Interactions Between Opioid Agonist Therapy and Antiretroviral Medications. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2006, 41: 563-572. PMID: 16652030, DOI: 10.1097/01.qai.0000219769.89679.ec.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsOpioid agonist therapyDrug interactionsAgonist therapyAntiretroviral therapyAntiretroviral medicationsImportant pharmacokinetic drug interactionsClinical case seriesImportant clinical consequencesClass of agentsHIV/AIDSPharmacokinetic interaction studyAntiretroviral agentsCase seriesOpioid dependenceHIV treatmentTreatable diseaseHIV therapyClinical consequencesFollowing keywordsMethadoneTherapyClinical implicationsLanguage articlesMedicationsDrug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine
McCance‐Katz E, Rainey PM, Smith P, Morse GD, Friedland G, Boyarsky B, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Delavirdine. American Journal On Addictions 2006, 15: 23-34. PMID: 16449090, DOI: 10.1080/10550490500419029.Peer-Reviewed Original ResearchConceptsDrug interactionsObjective Opioid Withdrawal ScaleSeven-day study periodNon-nucleoside reverse transcriptase inhibitorMini-Mental State ExaminationOpioid withdrawal symptomsOpioid Withdrawal ScaleClinical pharmacology studiesOpioid-dependent individualsReverse transcriptase inhibitorLAAM treatmentMethadone clearanceOpioid pharmacokineticsOpioid therapyOpioid toxicityAntiretroviral medicationsHIV outcomesPharmacodynamic interactionsCardiac toxicityWithdrawal symptomsAdverse symptomsTranscriptase inhibitorWithdrawal ScaleAcetyl methadolPharmacology studies
2004
Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir
McCance‐Katz E, Rainey PM, Smith P, Morse G, Friedland G, Gourevitch M, Jatlow P. Drug Interactions between Opioids and Antiretroviral Medications: Interaction between Methadone, LAAM, and Nelfinavir. American Journal On Addictions 2004, 13: 163-180. PMID: 15204667, DOI: 10.1080/10550490490436037.Peer-Reviewed Original ResearchConceptsDrug interactionsMetabolite exposureClinical pharmacology studiesInjection drug usersNelfinavir concentrationsOpiate medicationsOpiate therapyMethadone exposureAntiretroviral medicationsHIV outcomesDay study periodPharmacology studiesDrug usersMethadoneNelfinavirLAAMStudy periodMedicationsMinimal overall changeProtease inhibitorsExposureToxicityOverall changeAntiretroviralsOpioids
1999
Tuberculosis and HIV infection
Buitrago M, Friedland G. Tuberculosis and HIV infection. Current Infectious Disease Reports 1999, 1: 105-109. PMID: 11095774, DOI: 10.1007/s11908-999-0017-3.ChaptersProphylaxis of tuberculosisExpert consensus panelAntituberculous regimensAntiretroviral medicationsHIV infectionImportant new recommendationsEquivalent efficacyDrug interactionsConsensus panelShort courseLarge-scale studiesTuberculosisProphylaxisRegimensRifampinTreatmentNew recommendationsMedicationsHIVRifabutinInfectionIndividuals